ILMNIllumina, Inc.
Illumina, Inc. sells sequencing platforms and software for genomic research, clinical diagnostics, and life sciences applications. The next catalyst is Nov 6, 2026 — Q3 2026 Earnings Release, which will test the company’s ability to deliver on its recent acquisition of Clario Holdings and sustain revenue growth amid a challenging market.
- Illumina’s revenue fell 0.7% YoY in 2026, but free cash flow remains robust at $1.74B TTM.
- The company maintains a healthy debt-to-equity ratio of 0.50x and a net margin of 18.4%.
- Shareholders’ equity stands at $2.72B, with a diluted EPS of $1.35.
The schedule
- Fri6Nov
- Tue9Feb
- Fri7May
- Fri30Jul
Past
- Mon15Jun
Actual outcome: Bull · $271.20 at outcome
ILMN delivered a strong earnings report with higher-than-expected revenue and EPS, accompanied by optimistic long-term guidance. The results exceeded analyst expectations, signaling improved performance and future growth potential. The move reflects renewed investor confidence in the company's strategic direction and operational execution. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-07: +68.7% from 2026-06-18 (~2.6σ). Target date 2026-09-15 reached; move through 2026-10-07 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-08: +65.9% from 2026-06-22 (~2.5σ). Target date 2026-09-15 reached; move through 2026-10-08 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-09: +60.3% from 2026-06-23 (~2.3σ). Target date 2026-09-15 reached; move through 2026-10-09 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-12: +58.9% from 2026-06-24 (~2.2σ). Target date 2026-09-15 reached; move through 2026-10-12 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-13: +55.9% from 2026-06-25 (~2.1σ). Target date 2026-09-15 reached; move through 2026-10-13 observed.
ILMN delivered a strong earnings report with higher-than-expected revenue and EPS, accompanied by optimistic long-term guidance. The results exceeded analyst expectations, signaling improved performance and future growth potential. The move reflects renewed investor confidence in the company's strategic direction and operational execution. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-07: +68.7% from 2026-06-18 (~2.6σ). Target date 2026-09-15 reached; move through 2026-10-07 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-08: +65.9% from 2026-06-22 (~2.5σ). Target date 2026-09-15 reached; move through 2026-10-08 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-09: +60.3% from 2026-06-23 (~2.3σ). Target date 2026-09-15 reached; move through 2026-10-09 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-12: +58.9% from 2026-06-24 (~2.2σ). Target date 2026-09-15 reached; move through 2026-10-12 observed. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-13: +55.9% from 2026-06-25 (~2.1σ). Target date 2026-09-15 reached; move through 2026-10-13 observed.
- Thu28May
Actual outcome: Bull · $162.32 at outcome
Price reached or exceeded bull target ($170.00) at outcome date.
Price reached or exceeded bull target ($170.00) at outcome date.
- Thu5Feb
Actual outcome: Bear · $122.35 at outcome
Illumina reported a Q4 EPS and revenue beat, but the stock immediately dropped 10% and continued to decline, settling well below the $130 bear floor. The negative reaction was driven by investor disappointment over margin performance and concerns regarding the pace of high-margin consumables pull-through, which failed to meet the high expectations necessary to justify the company's valuation post-GRAIL spin-off.
Illumina reported a Q4 EPS and revenue beat, but the stock immediately dropped 10% and continued to decline, settling well below the $130 bear floor. The negative reaction was driven by investor disappointment over margin performance and concerns regarding the pace of high-margin consumables pull-through, which failed to meet the high expectations necessary to justify the company's valuation post-GRAIL spin-off.
